• RI - Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
    • português (Brasil)
    • English
    • español
  • Sobre
    • RI Unifesp
    • Documentos
    • Tutoriais
    • Perguntas frequentes
    • Atendimento
    • Equipe
  • English 
    • português (Brasil)
    • English
    • español
    • português (Brasil)
    • English
    • español
  • Login
View Item 
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
  •   DSpace Home
  • Escola Paulista de Medicina (EPM)
  • EPM - Artigos
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Identification of inhibitors to Trypanosoma cruzi Sirtuins based on compounds developed to human enzymes

Thumbnail
View/Open
Artigo Completo (2.907Mb)
Date
2020
Author
Bastos, Tanira Matutino
Soares, Milena Botelho Pereira
Franco, Caio Haddad
Alcântara, Laura
Antonini, Lorenzo
Sabatino, Manuela
Mautone, Nicola
Freitas-Junior, Lucio Holanda
Moraes, Carolina Borsoi
Ragno, Rino
Rotili, Dante
Schenkman, Sergio [UNIFESP]
Mai, Antonello
Moretti, Nilmar Silvio [UNIFESP]
Type
Artigo
Is part of
International Journal of Molecular Sciences
DOI
doi:10.3390/ijms21103659
Metadata
Show full item record
Abstract
Chagas disease is an illness caused by the protozoan parasite Trypanosoma cruzi, a↵ecting more than 7 million people in the world. Benznidazole and nifurtimox are the only drugs available for treatment and in addition to causing several side e↵ects, are only satisfactory in the acute phase of the disease. Sirtuins are NAD+-dependent deacetylases involved in several biological processes, which have become drug target candidates in various disease settings. T. cruzi presents two sirtuins, one cytosolic (TcSir2rp1) and the latter mitochondrial (TcSir2rp3). Here, we characterized the e↵ects of human sirtuin inhibitors against T. cruzi sirtuins as an initial approach to develop specific parasite inhibitors. We found that, of 33 compounds tested, two inhibited TcSir2rp1 (15 and 17), while other five inhibited TcSir2rp3 (8, 12, 13, 30, and 32), indicating that specific inhibitors can be devised for each one of the enzymes. Furthermore, all inhibiting compounds prevented parasite proliferation in cultured mammalian cells. When combining the most efective inhibitors with benznidazole at least two compounds, 17 and 32, demonstrated synergistic effects. Altogether, these results support the importance of exploring T. cruzi sirtuins as drug targets and provide key elements to develop specific inhibitors for these enzymes as potential targets for Chagas disease treatment.
Keywords
Sirtuins
Trypanosoma cruzi
Sirtuin inhibitors
Deacetylation
Sponsorship
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
URI
https://repositorio.unifesp.br/xmlui/handle/11600/62314
Collections
  • EPM - Artigos [16058]

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsBy Submit DateThis CollectionBy Issue DateAuthorsTitlesSubjectsBy Submit Date

My Account

Login

Statistics

View Usage Statistics

DSpace software copyright © 2002-2016  DuraSpace
Contact Us
Theme by 
Atmire NV